Tripathy Spotlights the State of Treatment in Metastatic HER2+ Breast Cancer | OncLive

Tripathy Spotlights the State of Treatment in Metastatic HER2+ Breast Cancer

September 21, 2020

Partner | Cancer Centers

In our exclusive interview, Dr. Tripathy discusses the state of treatment in metastatic HER2-positive breast cancer, current sequencing strategies, and targeted agents under evaluation in this setting.

Welcome to a very special edition of OncLive® On Air! I’m your host today, Caroline Seymour.

OncLive® On Air is a podcast from OncLive, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

Today, we had the pleasure of speaking with Debu Tripathy, MD, to discuss recent therapeutic additions to the HER2-positive breast cancer armamentarium.

In our exclusive interview, Dr. Tripathy, professor and chairman of the Department of Breast Medical Oncology in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses the state of treatment in metastatic HER2-positive breast cancer, current sequencing strategies, and targeted agents under evaluation in this setting.


x